
AMENDMENTS TO THE CLAIMS

- 1-41. (Cancelled)
- 42. (Withdrawn currently amended) The compound according to claim 163, or a pharmaceutically acceptable salt thereof, wherein X is selected from the group consisting of Ac, H, and ASAL, optionally iodinated in position 5 to yield the group 2-hydroxy-4-azido-5-iodo benzoyl.
- 43. (Withdrawn currently amended) The compound according to claim 163, or a pharmaceutically acceptable salt thereof, wherein R₇ is NH₂.
 - 44-49. (Cancelled)
- 50. (Currently amended) The compound according to claim 163, or a pharmaceutically acceptable salt thereof, wherein R_g is the amino acid side chain of Asn, D-4Hyp, or L-/D-Pro when said compound is a linear peptide, wherein, when R_g is the amino acid side chain of D-4Hyp or L-/D-Pro, the side chain is cyclized by attachment to the N atom bonded to the C atom to which R_g is attached.

- 51. (Withdrawn currently amended) The compound according to claim 163, or a pharmaceutically acceptable salt thereof, wherein R_h is the amino acid side chain of Pro, Pro or D-Pro, or D-Hyp, wherein the side chain is cyclized by attachment to the N atom bonded to the C atom to which R_h is attached.
- 52. (Withdrawn currently amended) The compound according to claim 163, or a pharmaceutically acceptable salt thereof, wherein R_i is the amino acid side chain of Tyr or D-Tyr.
- 53. (Withdrawn currently amended) The compound according to claim 163, or a pharmaceutically acceptable salt thereof, wherein R_j is the amino acid side chain of Asn or Gln.
 - 54-162. (Cancelled).
 - 163. (Currently Amended) A compound having the formula:



or a retro form an all D form or a retro all D form thereof, said compound optionally being cyclic through a covalent bond between N* and C*;

wherein:

X is H, Ac, TFa, DBF, ASAL optionally iodinated, or HP;

land n are 1;

each of j, k, l, m, n, p, p and q is are independently 0 or 1;

 R_a is the side chain of Hyp or Pro, which is cyclized by attachment to the N atom bonded to the C atom to which R_a is attached;

R_b is the side chain of Hyp or Pro, which is cyclized by attachment to the N atom bonded to the C atom to which R_a is attached;

R_c is the side chain of Gly-or-Sar;

R_d is the side chain of Ala, D-Ala, or Gly;

R_e-is the acid side chain of Ala;

R_f is the acid side chain of Ala, Sar, or Gly;

R_g is the side chain of L-Hyp, D-Hyp, Pro, D-Pro, Ncg, A2C, Sar, Gly, Asn, D-Asn, T4c, or Pc, Lys, or Thio-Pro if the compound is a cyclic compound, or R_g is the side

chain of D-Hyp, Pro, D-Pro, Ncg, A2C, Sar, Gly, Asn, D-Asn, T4c, or Pc, Lys, or Thio-Pro if the compound is a linear peptide, wherein said side chain of L-Hyp, D-Hyp, Pro, D-Pro, or Thio-Pro is cyclized by attachment to the N atom bonded to the C atom to which R_g is attached;

R_h is the side chain of Pro, D-Pro, <u>or</u> Ala, D-Hyp, Asn, or Thio Pro, wherein said side chain of Pro, <u>Pro or</u> D-Pro, <u>D Hyp, or Thio Pro</u> is cyclized by attachment to the N atom bonded to the C atom to which R_h is attached;

 R_i is the side chain of Gly, Phe, D-Phe, Tyr, Tyr or D-Tyr, wherein the aromatic ring of said Phe, D-Phe, Tyr, or D-Tyr side chain is optionally substituted with one or more halogen groups;

R_i is the side chain of Gln, Gln or Asn, D-Asp, or Cys;

R₇ is OH or NH₂, or is absent if the compound is cyclized between N* and C*, or a pharmaceutically acceptable salt thereof.

164. (Cancelled)

165. (Withdrawn – currently amended) The compound of claim 163, wherein said compound is cyclo(-Gly-Ala-Gly-Hyp-Pro-Tyr-Asn-) (SEQ ID NO:287), or a pharmaceutically acceptable salt thereof.

- 166. (Withdrawn currently amended) The compound of claim 163, wherein said compound is cyclo(-Tyr-Pro-4Hyp-Gly-Ala-Gly-Asn-) (SEQ ID NO:174), or a pharmaceutically acceptable salt thereof.
- 167. (Withdrawn currently amended) The compound of claim 163, wherein said compound is cyclo(-Gly-Ala-Gly-Pro-Pro-Tyr-Asn-) (SEQ ID NO:288), or a pharmaceutically acceptable salt thereof.
- 168. (Withdrawn currently amended) The compound of claim 163, wherein said compound is cyclo(-Gly-Ala-Gly-Pro-Pro-Tyr-Gln-), or a pharmaceutically acceptable salt thereof.
- 169. (Withdrawn currently amended) The compound of claim 163, wherein said compound is Gly-Ala-Gly-Pro-Pro-Tyr-NH₂, or a pharmaceutically acceptable salt thereof.
- 170. (Withdrawn currently amended) The compound of claim 163, wherein said compound is Ac-D-Tyr-D-Pro-D-Pro-Gly-D-Ala-Gly-NH₂, or a pharmaceutically acceptable salt thereof.

- 171. (Withdrawn currently amended) The compound of claim 163, wherein said compound is Ac-D-Tyr-D-Hyp-D-Hyp-Gly-D-Ala-Gly-NH₂, or a pharmaceutically acceptable salt thereof.
- 172. (Withdrawn currently amended) The compound of claim 163, wherein said compound is Gly-Ala-Gly-Asn-Tyr-NH₂ (SEQ ID NO:254), or a pharmaceutically acceptable salt thereof.
- 173. (Withdrawn currently amended) The compound of claim 163 195, wherein said compound is Ala-Gly-Asn-Tyr, or a pharmaceutically acceptable salt thereof.
- 174. (Withdrawn currently amended) The compound of claim 163 195, wherein said compound is Gly-Ala-Asn-Tyr-NH₂, or a pharmaceutically acceptable salt thereof.
- 175. (Withdrawn currently amended) The compound of claim 163 195, wherein said compound is Ac-Ala-Gly-Asn-Tyr, or a pharmaceutically acceptable salt thereof.
- 176. (Withdrawn currently amended) The compound of claim 163 195, wherein said compound is Ac-Gly-Asn-Tyr, or a pharmaceutically acceptable salt thereof.

- 177. (Withdrawn currently amended) The compound of claim 163 195, wherein said compound is Gly-Asn-Tyr, or a pharmaceutically acceptable salt thereof.
- 178. (Withdrawn currently amended) The compound of claim 163 195, wherein said compound is Ac-D-Tyr-D-Asn-Gly-NH₂, or a pharmaceutically acceptable salt thereof.
- 179. (Withdrawn currently amended) The compound of claim 163 195, wherein said compound is D-Tyr-D-Asn-Gly-NH₂, or a pharmaceutically acceptable salt thereof.
- 180. (Withdrawn currently amended) The compound of claim 163 195, wherein said compound is Gly-D-Asn-Tyr, or a pharmaceutically acceptable salt thereof.
- 181. (Withdrawn currently amended) The compound of claim 163 195, wherein said compound is Tyr-Asn-Gly-NH₂, or a pharmaceutically acceptable salt thereof.
- 182. (Withdrawn currently amended) The compound of claim 163 195, wherein said compound is Gly-Gly-Tyr-NH₂, or a pharmaceutically acceptable salt thereof.

- 183. (Withdrawn currently amended) The compound of claim 163 195, wherein said compound is Gly-D-Asn-Tyr-NH₂, or a pharmaceutically acceptable salt thereof.
- 184. (Withdrawn currently amended) The compound of claim 163 195, wherein said compound is Tyr-D-Asn-Gly, or a pharmaceutically acceptable salt thereof.
- 185. (Withdrawn currently amended) The compound of claim 163 195, wherein said compound is Ac-Tyr-D-Asn-Gly, or a pharmaceutically acceptable salt thereof.
- 186. (Withdrawn currently amended) The compound of claim 163 195, wherein said compound is Ac-Gly-D-Asn-Tyr-NH₂, or a pharmaceutically acceptable salt thereof.
- 187. (Withdrawn currently amended) The compound of claim 163 195, wherein said compound is Tyr-D-Asn-Gly-NH₂, or a pharmaceutically acceptable salt thereof.
- 188. (Withdrawn currently amended) The compound of claim 163 195, wherein said compound is Ac-Tyr-D-Asn-Gly-NH₂, or a pharmaceutically acceptable salt thereof.
- 189. (Withdrawn currently amended) The compound of claim 163 195, wherein said compound is Gly-Ala-Tyr-NH₂, or a pharmaceutically acceptable salt thereof.

- 190. (Withdrawn currently amended) The compound of claim 163 195, wherein said compound is Ac-Gly-Ala-Tyr-NH₂, or a pharmaceutically acceptable salt thereof.
- 191. (Withdrawn currently amended) The compound of claim 163 195, wherein said compound is Gly-Asp-Tyr-NH₂, or a pharmaceutically acceptable salt thereof.
- 192. (Withdrawn currently amended) The compound of claim 163 195, wherein said compound is Tyr-Asn-Gly, or a pharmaceutically acceptable salt thereof.
- 193. (Withdrawn currently amended) The compound of claim 163 195, wherein said compound is Tyr-Asp-Gly, or a pharmaceutically acceptable salt thereof.
- 194. (Currently amended) The compound of claim 163, or a pharmaceutically acceptable salt thereof, wherein X is Ac or H and R_g is selected from the group consisting of Pro, D-Pro, Hyp, D-Hyp, Gly, or Asn.
 - 195. (New) A compound comprising the formula:

$$X \xrightarrow{R_d} \left(\begin{array}{c} H \\ N \\ N \end{array} \right) \xrightarrow{R_f} \left(\begin{array}{c} R_g \\ N \\ N \end{array} \right) \xrightarrow{R_7} \left(\begin{array}{c} R_1 \\ N \\ N \end{array} \right) \xrightarrow{R_7} \left(\begin{array}{c} R_1 \\ N \\ N \end{array} \right) \xrightarrow{R_7} \left(\begin{array}{c} R_1 \\ N \\ N \end{array} \right) \xrightarrow{R_7} \left(\begin{array}{c} R_1 \\ N \\ N \end{array} \right) \xrightarrow{R_7} \left(\begin{array}{c} R_1 \\ N \\ N \end{array} \right) \xrightarrow{R_7} \left(\begin{array}{c} R_1 \\ N \\ N \end{array} \right) \xrightarrow{R_7} \left(\begin{array}{c} R_1 \\ N \\ N \end{array} \right) \xrightarrow{R_7} \left(\begin{array}{c} R_1 \\ N \\ N \end{array} \right) \xrightarrow{R_7} \left(\begin{array}{c} R_1 \\ N \\ N \end{array} \right) \xrightarrow{R_7} \left(\begin{array}{c} R_1 \\ N \\ N \end{array} \right) \xrightarrow{R_7} \left(\begin{array}{c} R_1 \\ N \\ N \end{array} \right) \xrightarrow{R_7} \left(\begin{array}{c} R_1 \\ N \\ N \end{array} \right) \xrightarrow{R_7} \left(\begin{array}{c} R_1 \\ N \\ N \end{array} \right) \xrightarrow{R_7} \left(\begin{array}{c} R_1 \\ N \\ N \end{array} \right) \xrightarrow{R_7} \left(\begin{array}{c} R_1 \\ N \\ N \end{array} \right) \xrightarrow{R_7} \left(\begin{array}{c} R_1 \\ N \\ N \end{array} \right) \xrightarrow{R_7} \left(\begin{array}{c} R_1 \\ N \\ N \end{array} \right) \xrightarrow{R_7} \left(\begin{array}{c} R_1 \\ N \\ N \end{array} \right) \xrightarrow{R_7} \left(\begin{array}{c} R_1 \\ N \\ N \end{array} \right) \xrightarrow{R_7} \left(\begin{array}{c} R_1 \\ N \\ N \end{array} \right) \xrightarrow{R_7} \left(\begin{array}{c} R_1 \\ N \\ N \end{array} \right) \xrightarrow{R_7} \left(\begin{array}{c} R_1 \\ N \\ N \end{array} \right) \xrightarrow{R_7} \left(\begin{array}{c} R_1 \\ N \\ N \end{array} \right) \xrightarrow{R_7} \left(\begin{array}{c} R_1 \\ N \\ N \end{array} \right) \xrightarrow{R_7} \left(\begin{array}{c} R_1 \\ N \\ N \end{array} \right) \xrightarrow{R_7} \left(\begin{array}{c} R_1 \\ N \\ N \end{array} \right) \xrightarrow{R_7} \left(\begin{array}{c} R_1 \\ N \\ N \end{array} \right) \xrightarrow{R_7} \left(\begin{array}{c} R_1 \\ N \\ N \end{array} \right) \xrightarrow{R_7} \left(\begin{array}{c} R_1 \\ N \\ N \end{array} \right) \xrightarrow{R_7} \left(\begin{array}{c} R_1 \\ N \\ N \end{array} \right) \xrightarrow{R_7} \left(\begin{array}{c} R_1 \\ N \\ N \end{array} \right) \xrightarrow{R_7} \left(\begin{array}{c} R_1 \\ N \\ N \end{array} \right) \xrightarrow{R_7} \left(\begin{array}{c} R_1 \\ N \\ N \end{array} \right) \xrightarrow{R_7} \left(\begin{array}{c} R_1 \\ N \end{array} \right)$$

a retro, all-D, or retro all-D form thereof; or a pharmaceutically acceptable salt thereof;

wherein

n is 0 or 1;

X is H or Ac;

R_d is the amino acid side chain of Ala or Gly;

R_f is the side chain of Ala or Gly;

 R_g is the side chain of any amino acid except the side chain of L-4Hyp or a moiety of formula II or IIa;

R_i is the amino acid side chain of Tyr; and

R₇ is OH or NH₂;

wherein formula II is represented by:

wherein n is an integer having the value 3, 4, or 5, and R represents an optional substituent selected from the group consisting of halogen, phenyl, hydroxy, NH₂, and C(1-6)alkyl, and

wherein formula IIa is represented by

wherein n is an integer having the value 0, 1, 2, and 3, p is an integer having the value 0, 1, 2, and 3, Z represents O or S, and R represents an optional substituent selected from the group consisting of halogen, phenyl, hydroxy, NH₂ and C(1-6)alkyl.

196. (New) The peptide of claim 195, or a pharmaceutically acceptable salt thereof, wherein $R_{\rm g}$ is the amino acid side chain of Asn.